Market Place
Sourcing Support
Kezar Life Sciences Reports Positive Portola Trial Safety Review
17 Oct 2024 //
BUSINESSWIRE
Kezar halts mid-stage lupus study after four deaths
01 Oct 2024 //
FIERCE BIOTECH
Kezar Life Sciences Ends Enrollment In Ph2 Trial For Zetomipzomib
30 Sep 2024 //
BUSINESSWIRE
Kezar Life Sciences Reports Q2 2024 Results And Business Update
13 Aug 2024 //
BUSINESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Kezar Life Sciences Q1 2024 Financials, Business Update
09 May 2024 //
BUSINESSWIRE
Everest Medicines Announces Investigational NDA Acceptance of Zetomipzomib
03 Dec 2023 //
PR NEWSWIRE
Kezar and Everest Medicines Enter into an Agreement to Develop Zetomipzomib
20 Sep 2023 //
BUSINESSWIRE
Kezar Presents Complete Results from Phase 2 Trial Evaluating Zetomipzomib
14 Nov 2022 //
BUSINESSWIRE
Kezar to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib
14 Oct 2022 //
BUSINESSWIRE
Kezar Receives FDA Clearance of IND for Zetomipzomib for Autoimmune Hepatitis
03 Oct 2022 //
BUSINESSWIRE
Kezar Life Sciences Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Kezar Life Sciences Announces Positive Topline Results from MISSION PII Trial
27 Jun 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.